Su Ding-Feng
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Curr Opin Cardiol. 2006 Sep;21(5):486-91. doi: 10.1097/01.hco.0000240587.14463.58.
Blood pressure variability, a quantitative index for the spontaneous variation in blood pressure, has been proposed as a risk factor for end-organ damage and to determine the efficacy of hypertension treatment.
Animal studies indicate that blood pressure variability is as important as blood pressure level in determining end-organ damage, and that high blood pressure variability is associated with end-organ damage, including myocardial lesions, aortic hypertrophy, vascular remodeling and renal damage. Although the organ damage induced by high blood pressure variability was similar to that induced by hypertension, comparative studies in sinoaortic-denervated and spontaneously hypertensive rats revealed that aortic hypertrophy is a sensitive index of high blood pressure variability, and left ventricular hypertrophy is a sensitive index of high blood pressure level. The possible mechanisms for high blood pressure variability-induced end-organ damage include: direct endothelial lesions, renin-angiotensin system activation, inflammation initiation and cardiomyocyte apoptosis augmentation. Blood pressure variability reduction contributes importantly to the organ-protective effect of some antihypertensive drugs.
Although animal studies suggest some advantages in blood pressure variability measurements, clinical trials are necessary before the widespread use of blood pressure variability as a predictor of hypertensive organ damage and a new strategy for the treatment of hypertension.
血压变异性是血压自发变化的定量指标,已被提出作为终末器官损害的危险因素及判定高血压治疗疗效的指标。
动物研究表明,血压变异性在判定终末器官损害方面与血压水平同样重要,且高血压变异性与终末器官损害相关,包括心肌病变、主动脉肥厚、血管重塑和肾损害。尽管高血压变异性所致的器官损害与高血压所致的相似,但对去窦主动脉神经大鼠和自发性高血压大鼠的比较研究显示,主动脉肥厚是高血压变异性的敏感指标,而左心室肥厚是高血压水平的敏感指标。高血压变异性所致终末器官损害的可能机制包括:直接的内皮损伤、肾素-血管紧张素系统激活、炎症启动及心肌细胞凋亡增加。降低血压变异性对某些降压药物的器官保护作用有重要贡献。
尽管动物研究提示血压变异性测量有一些优势,但在将血压变异性广泛用作高血压器官损害的预测指标及高血压治疗的新策略之前,仍需要进行临床试验。